Citadel Advisors
RPRX icon

Citadel Advisors’s Royalty Pharma RPRX Stock Holding History

Citadel Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76M Sell
1,354,640
-1,326,429
-49% -$69M 0.01% 1188
2026
Q1 		$129M Sell
2,681,069
-2,592,796
-49% -$114M 0.02% 661
2025
Q4 		$204M Buy
5,273,865
+4,879,192
+1,236% +$186M 0.03% 480
2025
Q3 		$13.9M Sell
394,673
-132,615
-25% -$4.8M ﹤0.01% 2777
2025
Q2 		$19M Sell
527,288
-1,538,488
-74% -$51M ﹤0.01% 2208
2025
Q1 		$64.3M Sell
2,065,776
-832,188
-29% -$26.4M 0.01% 963
2024
Q4 		$73.9M Buy
+2,897,964
New +$76.8M 0.01% 951
2024
Q2 		– Sell
-97,919
Closed -$2.71M – 15228
2024
Q1 		$2.97M Sell
97,919
-389,101
-80% -$11.5M ﹤0.01% 4807
2023
Q4 		$13.7M Buy
487,020
+363,939
+296% +$10M ﹤0.01% 2448
2023
Q3 		$3.34M Sell
123,081
-532,291
-81% -$15.8M ﹤0.01% 4297
2023
Q2 		$20.1M Sell
655,372
-423,582
-39% -$14.3M ﹤0.01% 1877
2023
Q1 		$38.9M Buy
1,078,954
+567,014
+111% +$21M 0.01% 1302
2022
Q4 		$20.2M Buy
511,940
+175,979
+52% +$7.35M ﹤0.01% 1952
2022
Q3 		$13.5M Buy
335,961
+76,116
+29% +$3.25M ﹤0.01% 2355
2022
Q2 		$10.9M Sell
259,845
-1,323,288
-84% -$54.2M ﹤0.01% 2572
2022
Q1 		$61.7M Buy
1,583,133
+1,371,252
+647% +$53.8M 0.01% 969
2021
Q4 		$8.44M Buy
211,881
+99,702
+89% +$3.87M ﹤0.01% 3351
2021
Q3 		$4.05M Sell
112,179
-377,172
-77% -$14.7M ﹤0.01% 4718
2021
Q2 		$20.1M Buy
489,351
+351,746
+256% +$15M ﹤0.01% 2081
2021
Q1 		$6M Sell
137,605
-186,636
-58% -$8.85M ﹤0.01% 3867
2020
Q4 		$16.2M Buy
324,241
+256,692
+380% +$10.9M ﹤0.01% 2037
2020
Q3 		$2.84M Sell
67,549
-856,056
-93% -$36.7M ﹤0.01% 4075
2020
Q2 		$44.8M Buy
+923,605
New +$45.7M 0.02% 869

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's RPRX Position: Q2 2026 in Review

Citadel Advisors reduced its Royalty Pharma (RPRX) stake by 49% in Q2 2026, selling an estimated $69M and leaving 1,354,640 shares worth $76M. The position accounts for 0.01% of the portfolio, ranked #1188.

Citadel Advisors first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $204M in Q4 2025. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Citadel Advisors held 1,354,640 shares of Royalty Pharma worth $76M as of Q2 2026.
  • Citadel Advisors sold 1,326,429 Royalty Pharma shares in Q2 2026, an estimated $69M.
  • Royalty Pharma made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1188 holding.
  • Citadel Advisors first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Royalty Pharma position peaked at $204M in Q4 2025.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.